In a nutshell This study compared two chemotherapy combinations – R-DHAP and R-DHAOx – to see which caused less kidney damage in patients with non-Hodgkin lymphoma (NHL). The results showed that fewer patients receiving R-DHAOx developed poor kidney function than patients receiving R-DHAP. Some background Combinations of chemotherapy...
Read More
In a nutshell This study compared the safety and effectiveness of BCD-020 (biosimilar rituximab) to rituximab (Rituxan) in patients with non-Hodgkin’s lymphoma (NHL). This study found that BCD-020 was just as effective as standard rituximab, with manageable side effects. Some background Rituximab is commonly used in the treatment of NHL....
Read MoreIn a nutshell This study evaluated two different dosing approaches for busulfan (Busilvex) chemotherapy for patients with non-Hodgkin lymphoma (NHL) before an autologous stem cell transplant (SCT). The authors found that personalizing treatment dose for these patients was more effective than conventional weight-based dosing. Some background...
Read More
In a nutshell The study aimed to identify cardiovascular (heart and blood vessel) adverse drug reactions (CV-ADR) associated with ibrutinib treatment. This study concluded that severe and sometimes fatal cardiac events occur in patients exposed to ibrutinib. Some background Ibrutinib (Imbruvica) is a targeted therapy that can be used for...
Read MoreIn a nutshell This study investigated if there is a higher risk of cardiovascular disease (CVD) in cancer survivors. They found that cancer survivors have a higher risk of CVD. Some background Improved cancer detection and treatment has increased the rates of survival. The number of cancer survivors living for more than 10 years is growing. Some...
Read More
In a nutshell This study evaluated the effectiveness and safety of a new chemotherapy regimen for patients with non-Hodgkin’s lymphoma (NHL). This study concluded that this regimen was highly effective for these patients, but was associated with some side effects. Some background For patients with NHL, age is one determining factor for treatment...
Read More
In a nutshell This study aimed to investigate the safety and effectiveness of ublituximab, umbralisib and ibrutinib combination in patients with chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma (NHL). This study concluded that this combination appears safe and effective for these patients. Some background Patients...
Read More
In a nutshell This study investigated the long-term survival outcomes of patients with stage 1 non-Hodgkin’s lymphoma (NHL). This study concluded that these patients have favorable outcomes but may need follow-up after 5 years of remission (no cancer recurrence). Some background Most patients with early-stage (stage 1 – 2) NHL tend to have...
Read More
In a nutshell This study evaluated the impact of autoimmune conditions on the outcomes of patients with lymphoma. This study concluded that these conditions may negatively impact survival outcomes for these patients. Some background Autoimmune conditions are a group of diseases where the immune system attacks the body’s healthy tissues. One...
Read More
In a nutshell This study evaluated the impact of autoimmune conditions on the outcomes of patients with lymphoma. This study concluded that these conditions may negatively impact survival outcomes for these patients. Some background Autoimmune conditions are a group of diseases where the immune system attacks the body’s healthy tissues. One...
Read More
In a nutshell This study evaluated the outcomes of concurrent (at the same time) combination antiretroviral therapy (cART) and chemotherapy in HIV-positive patients with non-Hodgkin’s lymphoma (NHL). This study concluded that concurrent cART with chemotherapy was well-tolerated and allowed for faster immune recovery in these patients, but did not...
Read More
In a nutshell This study evaluated the safety and effectiveness of venetoclax (Venclexta) plus BR (bendamustine, rituximab) in patients with relapsed or refractory (does not respond to treatment) non-Hodgkin’s lymphoma (NHL). This study concluded that this treatment was tolerated and showed promising effectiveness in these patients. Some...
Read More
